A Multicenter, Randomized, Double-Blind, Flexible-Dosed, Placebo-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Tourette's Syndrome
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- 20 Feb 2019 Planned End Date changed from 19 Jul 2019 to 1 Apr 2020.
- 20 Feb 2019 Planned primary completion date changed from 19 Jul 2019 to 1 Apr 2020.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.